ArticleJournal of inflammation research2025
Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Advanced Lung Cancer Inflammation Index (ALI) is a newly introduced index that integrates inflammatory and nutritional statuses to assess malignancies. This study investigates the association between pre-immunotherapy ALI levels and clinical outcomes in recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) patients receiving immune checkpoint inhibitors (ICIs) therapy. Patients and Methods: We conducted an exploratory post hoc analysis of a multicenter, single-arm Phase 2 trial enrolling 153 patients with R/M NPC. This study evaluated the prognostic utility of the pretreatment ALI for overall survival (OS) and progression-free survival (PFS), along with its association with treatment response to ICIs. The optimal ALI cutoff was empirically derived from this cohort. Propensity score matching (PSM) was also applied to assess the independent association between pretreatment ALI and clinical outcomes. Results: Patients with low ALI scores demonstrated shorter OS and PFS compared to the high ALI group (OS: HR=4.07, p<0.001; PFS: HR=2.17, p<0.001). Low ALI was also associated with a lower disease control rate (DCR) (25.0% vs 58.7%, p=0.002), but showed no significant correlation with objective response rate (ORR) (15.6% vs 23.1%, p=0.361). In multivariate analysis incorporating propensity score-matched cohorts (n=62), ALI retained prognostic value for OS (HR=3.74, p=0.001) and PFS (HR=1.84, p=0.049). Conclusion: Our findings suggest that pretreatment ALI as a promising prognostic biomarker for R/M NPC patients treated with ICIs. Given the exploratory post hoc nature of this analysis, the use of an empirically derived cutoff without external validation and the modest sample size of the matched cohort, these results warrant validation in future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.